Vanvan Nguyen, PA
Medical · Henderson, NVNPI 1336737360
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,617 of the $7,417 with a category attached, or 89.2%. It is spread thinly across 34 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $32.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$930
- AstraZeneca$928
- Amgen$765
- Novo Nordisk$490
- AbbVie$471
- Intra-sana Laboratories$386
- plus $3K from 28 others
What the payments were for
- Consulting fees$80011%
- Food & beverage$6,61789%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 3 | $930 |
| AstraZeneca | 31 | $928 |
| Amgen(2 entities) | 15 | $765 |
| Novo Nordisk | 18 | $490 |
| AbbVie | 19 | $471 |
| Intra-sana Laboratories | 10 | $386 |
| Lucid Diagnostics Inc. | 5 | $355 |
| Boehringer Ingelheim | 11 | $305 |
| Lilly USA, LLC | 13 | $276 |
| Dexcom, Inc. | 12 | $254 |
| Pfizer | 11 | $240 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $238 |
| Boston Scientific | 7 | $211 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $205 |
| Bayer | 6 | $186 |
| Exact Sciences | 10 | $170 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $150 |
| Johnson & Johnson | 2 | $126 |
| Phathom Pharmaceuticals, Inc. | 2 | $124 |
| Axsome Therapeutics, Inc. | 1 | $112 |
| Corcept Therapeutics | 1 | $99 |
| Tactile Systems Technology Inc | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $38 |
| Genentech USA, Inc. | 3 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| GSK | 2 | $28 |
| Astellas Pharma US Inc | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
| Merck | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,049
- Reltone 200 Mg$320
- GLYCATE$320
- Reltone 400 Mg$320
- QULIPTA$226
- DEXCOM G7 GSS (161)$144
- DEXCOM STELO GLUCOSE BIOSENSOR$144
- Repatha$139
- KRYSTEXXA$127
- CAPLYTA$127
- FARXIGA$124
- XARELTO$123
- Kerendia$122
- AIMOVIG$121
- Ozempic$118
- Symbravo$112
- JARDIANCE$112
- SUPERION$111
- VOQUEZNA$108
- PAXLOVID$104
How this compares
$7,417 in reported general payments places this provider in the 90th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 56 | $79,454 |
| FarxigaDapagliflozin Propanediol | 36 | $54,215 |
| OzempicSemaglutide | 40 | $47,906 |
| EliquisApixaban | 28 | $27,961 |
| JanuviaSitagliptin Phosphate | 16 | $25,845 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $22,672 |
| Repatha SureclickEvolocumab | 13 | $10,646 |
| LinzessLinaclotide | 13 | $8,742 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,273 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,086 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 132 | $3,563 |
| Atorvastatin Calcium | 332 | $2,610 |
| Gabapentin | 59 | $1,265 |
| Famotidine | 66 | $1,193 |
| Diclofenac Sodium | 22 | $1,180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $305 | $86,72768 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $928 | $76,88758 claims |
| Novo NordiskOzempic | $490 | $47,90640 claims |
| PfizerEliquis | $240 | $27,96128 claims |
| MerckJanuvia | $18 | $25,84516 claims |
| AbbVieLinzess | $471 | $8,74213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 medical providers in Nevada.
Other medical in Henderson
- Payton CerdaHenderson$9K
- Sururat CoulibalyHenderson$8K
- Patrick YudezHenderson$6K
- Eric HaralsonHenderson$5K
- Kristine-Gem EstrellaHenderson$5K
- Elena ZalanHenderson$4K
- Jessica GdovinHenderson$3K
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.